Join to View Full Profile
321 1st Ave. N.,Alabaster, AL 35007
Phone+1 205-624-4325
Fax+1 205-620-6776
Dr. Beenken is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Samuel Beenken was a surgical oncologist in Birmingham, AL, but now consults in drug development and maintains a clinical practice centered on the management of chronic pain and addiction. He received his medical degree from University of Manitoba and has been in practice 48 years. He has published numerous peer-reviewed articles in his areas of expertise - most currently, targeted therapy for brain cancers. He and has written multiple book chapters in Surgical Oncology.
Education & Training
University of ManitobaClass of 1975
Certifications & Licensure
AL State Medical License 1990 - 2025
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Fenretinide in Treating Patients With Leukoplakia of the Mouth Start of enrollment: 1997 Jun 01
Publications & Presentations
PubMed
- 40 citationsThyroid carcinoma: Clinical practice guidelinesSteven I. Sherman, Peter Angelos, Douglas W. Ball, Samuel W. Beenken, David R. Byrd
Journal of the National Comprehensive Cancer Network. 2005-05-01 - 43 citationsBreast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor ModulatorCarol J. Fabian, Bruce F. Kimler, Julie Anderson, Ossama Tawfik, Matthew S. Mayo
Clinical Cancer Research. 2004-08-15 - 3 citationsTreatment options for Merkel cell carcinoma.Samuel W. Beenken, Marshall M. Urist
Journal of the National Comprehensive Cancer Network. 2004-01-01
Grant Support
- Retinoid Modulation Of TGFA, ERBB2, EGFR And LeukoplakiaNational Cancer Institute1995–1997
- Phase II Clinical Trials-4hpr In Breast NeoplasiaDivision Of Cancer Prevention And Control1995–1996
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
